Research Analysts Set Expectations for ANRO FY2029 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities research analysts at Wedbush issued their FY2029 EPS estimates for Alto Neuroscience in a report released on Thursday, March 20th. Wedbush analyst L. Chico expects that the company will post earnings of ($2.88) per share for the year. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share.

Separately, William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Alto Neuroscience has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $2.56 on Monday. The stock has a 50 day moving average price of $3.56 and a 200 day moving average price of $5.90. Alto Neuroscience has a 52-week low of $2.53 and a 52-week high of $18.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The firm has a market capitalization of $69.04 million and a P/E ratio of -1.01.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.09.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its stake in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after buying an additional 3,139 shares during the period. BNP Paribas Financial Markets increased its position in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after purchasing an additional 3,715 shares during the period. Deutsche Bank AG increased its position in Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Alto Neuroscience in the 4th quarter worth approximately $74,000. Finally, Jane Street Group LLC boosted its stake in shares of Alto Neuroscience by 72.0% during the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after purchasing an additional 7,783 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.